Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow OPTH by emailGet an email when OPTH pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about OPTH, unsubscribe in one click. Privacy
📣 What OPTH Says Is Next
next year · ““With both trials expected to begin enrolling patients next year, this timely appointment strengthens our ability to generate the data to bring these treatments to the underserved patient populations who need them most." Dr. Blough is a medical researcher with more than 20 years of experience directing research programs spanning bench science, pre-clinical studies, and clinical trials.”
Company press release, Sep 22, 2026 · SEC filing
first half of 2027 · “The trial is planned to be initiated in the first half of 2027, with dosing expected to be complete by the end of 2027.”
Company press release, Sep 10, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full OPTH picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OPTH and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.